The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
GentleIris stopped hormone-induced hair loss with diet changes but couldn't regrow lost hair. A reply suggested microneedling instead of Platelet-Rich Plasma Therapy (PRP) for hair regrowth.
Considering exosome stemcell injections for hair loss alongside minoxidil and finasteride. Some suggest trying dutasteride first due to its proven effectiveness.
A 22-year-old male is using Dutasteride, Minoxidil, RU58841, and Microneedling to treat hair loss and is wondering if he can regrow hair at his temples. Commenters suggest that he should continue the treatment as it takes time, with full results expected in 2-2.5 years.
Hair loss treatments ExoFlo and XoFlo use exosomes from stemcells to stimulate hair growth. The user seeks feedback on results from those who tried these treatments.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stemcells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
A 22-year-old is frustrated with ongoing hair loss despite using treatments like topical minoxidil, finasteride, microneedling, oral dutasteride, and oral minoxidil. Their dermatologist suggests treating scalp inflammation with oral tretinoin and using exosomes for alopecia.
The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.
A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
Microneedling before a hair transplant may harden the scalp and affect blood circulation, potentially impacting graft growth. Some users report successful transplants after microneedling, while others advise caution and consulting with a surgeon.
Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stemcell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.
The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.
A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.
The user is using topical minoxidil and oral finasteride for hair regrowth, with plans for a future hair transplant. They are considering additional treatments like dermastamping and exploring options for dutasteride, which is unavailable in their country.
The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.
A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.
Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.
Microneedling stimulates hair growth through stemcell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.
The user is considering a second hair transplant after previous treatments with finasteride and minoxidil failed to stop hair loss. Suggestions include trying dutasteride, oral minoxidil, scalp micropigmentation, or shaving the head.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Hair cloning may become available in 1-2 years in Japan, but widespread availability and affordability could take 7-15 years. Current treatments like finasteride are effective but may lose effectiveness over time.